Aurobindo Pharma has withdrawn the applications for EU Marketing Authorisations for ZEFYLTI and DYRUPEG due to not being able to obtain EU-GMP certification of their biosimilars manufacturing facility within the current Day 180 clock-stop period. The company plans to work with the agency to re-submit the applications at the earliest.